Researchers from the National Institutes of Health tested the drug in an experiment of cell cultures with live viruses, finding it can reduce COVID-19 infections by targeting an enzyme the virus needs to make copies of itself inside the body.
“We urgently need additional effective, accessible treatments for COVID-19,” Diana Bianchi, MD, director of the NIH’s National Institute of Child Health and Human Development, said in a news release. “An oral drug that prevents SARS-CoV-2 from replicating would be an important tool for reducing the severity of the disease.”
The NIH said it will conduct more preliminary studies on Tempo l and plans to study the drug in a clinical study of COVID-19.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
